AstraZeneca- Oxford COVID-19 vaccine 79% effective in US trial
22 Mar 2021
AstraZeneca said an independent safety committee conducted a specific review of the blood clots in the US trial, as well as cerebral venous sinus thrombosis (CVST), which is an extremely rare blood clot in the brain, with the help of an independent neurologist.